MX2013011526A - Derivados de isoxazol utiles como agentes antibacteriales . - Google Patents

Derivados de isoxazol utiles como agentes antibacteriales .

Info

Publication number
MX2013011526A
MX2013011526A MX2013011526A MX2013011526A MX2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A MX 2013011526 A MX2013011526 A MX 2013011526A
Authority
MX
Mexico
Prior art keywords
antibacterial agents
derivatives useful
isoxazole derivatives
formula
isoxazole
Prior art date
Application number
MX2013011526A
Other languages
English (en)
Spanish (es)
Inventor
Matthew F Brown
Jinshan Michael Chen
Michael Melnick
Justin I Montgomery
Usa Reilly
Joseph A Abramite
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013011526A publication Critical patent/MX2013011526A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013011526A 2011-04-08 2012-03-23 Derivados de isoxazol utiles como agentes antibacteriales . MX2013011526A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161473540P 2011-04-08 2011-04-08
PCT/IB2012/051406 WO2012137094A1 (en) 2011-04-08 2012-03-23 Isoxazole derivatives useful as antibacterial agents

Publications (1)

Publication Number Publication Date
MX2013011526A true MX2013011526A (es) 2013-12-06

Family

ID=45999906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011526A MX2013011526A (es) 2011-04-08 2012-03-23 Derivados de isoxazol utiles como agentes antibacteriales .

Country Status (14)

Country Link
US (1) US8748466B2 (enExample)
EP (1) EP2694488B1 (enExample)
JP (1) JP2014510132A (enExample)
KR (1) KR20130140868A (enExample)
CN (1) CN103717582B (enExample)
AU (1) AU2012238374B2 (enExample)
CA (1) CA2830920C (enExample)
DK (1) DK2694488T3 (enExample)
ES (1) ES2526687T3 (enExample)
IL (2) IL228799A (enExample)
MX (1) MX2013011526A (enExample)
SG (1) SG193367A1 (enExample)
WO (1) WO2012137094A1 (enExample)
ZA (1) ZA201306736B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334636A2 (en) 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体
AP3336A (en) 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137099A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
CN103717582B (zh) 2011-04-08 2015-09-30 辉瑞大药厂 用作抗菌剂的异*唑衍生物
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9937156B2 (en) * 2013-10-16 2018-04-10 The Board Of Regents Of The University Of Texas System Modulation of MRTF-A activity in pathologic fibrosis and wound healing
PL3083567T3 (pl) 2013-12-19 2018-08-31 Idorsia Pharmaceuticals Ltd Przeciwbakteryjne pochodne 1h-indazolu i 1h-indolu
AR099612A1 (es) * 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
EP3134401B1 (en) * 2014-04-22 2018-06-13 Novartis AG Isoxazoline hydroxamic acid derivatives as lpxc inhibitors
SG11201609286VA (en) 2014-05-16 2016-12-29 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
CA2963875A1 (en) 2014-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
CR20170260A (es) 2014-12-16 2017-08-21 Novartis Ag COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105848A1 (es) * 2015-08-31 2017-11-15 Actelion Pharmaceuticals Ltd Derivados heterocíclicos antibacterianos
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
US10590498B2 (en) * 2016-05-17 2020-03-17 Lawrence Livermore National Security, Llc Compounds for reactivation of acetylcholinesterase and related compositions methods and systems
ES2820502T3 (es) * 2016-06-14 2021-04-21 Novartis Ag Forma cristalina de (R)-4-(5-(ciclopropiletilinil)isoxazol-3-il)-N-hidroxi-2-metil-2-(metilsulfonil)butanamida como agente antibacteriano
DE102016113269A1 (de) 2016-07-19 2018-01-25 Osram Opto Semiconductors Gmbh Leuchtvorrichtung für ein mobiles endgerät
TWI604678B (zh) * 2016-09-07 2017-11-01 國立暨南國際大學 Radio transmission system
US10160724B2 (en) * 2016-09-28 2018-12-25 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
US11186548B2 (en) 2017-11-23 2021-11-30 Lawrence Livermore National Security, Llc Compounds for central reactivation of organophosphorus-based compound-inhibited acetylcholinesterase and/or inactivation of organophosphorus-based acetylcholinesterase inhibitors and related compositions methods and systems for making and using them
AU2019383674A1 (en) * 2018-11-21 2021-06-10 Taisho Pharmaceutical Co., Ltd. Novel imidazole derivative
CN111944719B (zh) * 2020-08-14 2022-04-29 暨南大学 一株二恶烷降解菌is20及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
AU749699B2 (en) 1998-02-07 2002-07-04 British Biotech Pharmaceuticals Limited Antibacterial agents
GB9925470D0 (en) 1999-10-27 1999-12-29 Smithkline Beecham Plc Novel compounds
WO2002074298A1 (en) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Il-6 production inhibitors
ES2180456B1 (es) * 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
KR101076018B1 (ko) 2003-01-08 2011-10-21 유니버시티 오브 워싱톤 항균제
GB0302431D0 (en) 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
US7495006B2 (en) 2004-12-10 2009-02-24 Emory University 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
WO2006118155A1 (ja) 2005-04-27 2006-11-09 Ishihara Sangyo Kaisha, Ltd. ビフェニル誘導体又はその塩、並びにそれらを有効成分として含有する農園芸用殺菌剤
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
JP2009520695A (ja) 2005-12-15 2009-05-28 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するn−ヒドロキシアミド誘導体
WO2007093904A1 (en) * 2006-02-14 2007-08-23 Pfizer Products Inc. Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents
US20080085893A1 (en) 2006-10-06 2008-04-10 Shyh-Ming Yang Matrix metalloprotease inhibitors
CN101016270B (zh) * 2006-12-30 2012-05-09 天津药物研究院 取代的哌嗪基苯基异噁唑啉衍生物及其用途
US7879911B2 (en) 2007-02-01 2011-02-01 Johnson Alan T Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
WO2008105515A1 (ja) 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
JP2011529964A (ja) 2008-08-04 2011-12-15 シェーリング コーポレイション 抗菌剤としての尿素誘導体
WO2010024356A1 (ja) 2008-08-27 2010-03-04 大正製薬株式会社 ナフチリジン-n-オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
EP2334636A2 (en) * 2008-09-19 2011-06-22 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
JP5793766B2 (ja) 2009-12-16 2015-10-14 ファイザー・インク 抗菌剤として有用なn−結合型ヒドロキサム酸誘導体
AP3336A (en) 2011-03-07 2015-07-31 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137099A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
CN103717582B (zh) 2011-04-08 2015-09-30 辉瑞大药厂 用作抗菌剂的异*唑衍生物

Also Published As

Publication number Publication date
AU2012238374A1 (en) 2013-09-26
AU2012238374B2 (en) 2015-04-02
US8748466B2 (en) 2014-06-10
DK2694488T3 (en) 2014-12-15
JP2014510132A (ja) 2014-04-24
CN103717582B (zh) 2015-09-30
SG193367A1 (en) 2013-10-30
EP2694488A1 (en) 2014-02-12
IL240078A0 (en) 2015-08-31
CA2830920A1 (en) 2012-10-11
CN103717582A (zh) 2014-04-09
KR20130140868A (ko) 2013-12-24
ES2526687T3 (es) 2015-01-14
CA2830920C (en) 2015-07-14
IL228799A (en) 2015-08-31
IL228799A0 (en) 2013-12-31
WO2012137094A1 (en) 2012-10-11
EP2694488B1 (en) 2014-11-12
ZA201306736B (en) 2014-11-26
US20140024690A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
PH12013501780A1 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2013011432A (es) Derivados de imidazol, pirazol, y triazol utiles como agentes antibacterianos.
WO2011045703A3 (en) C-linked hydroxamic acid derivatives useful as antibacterial agents
MX2013005994A (es) Monobactamas.
PH12016502436A1 (en) Anti-infective compounds
CY1122305T1 (el) Ενωσεις υδροξαζολης υδροξαμικου οξεος ως αναστολεις lpxc
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
PH12014502224A1 (en) Heterobicyclic compounds as beta-lactamase inhibitors
EA201390274A1 (ru) Борсодержащие малые молекулы
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014CN04558A (enExample)
EA201492210A1 (ru) Соединения, ингибирующие активность катехол-o-метилтрансферазы
MY189098A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
MX367309B (es) Nuevos compuestos antibacterianos.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
HK1222339A1 (zh) 金属-β-内酰胺酶的抑制剂
EA201300092A1 (ru) Замещенные производные оксадиазола
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
MX363480B (es) Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi.
GEP20156264B (en) Use of nifuratel to treat infections caused by clostridium species
CY1115821T1 (el) Παραγωγα ν-συνδεδεμενου υδροξαμικου οξεος χρησιμα ως αντιβακτηριακοι παραγοντες
PL398895A1 (pl) Zastosowanie styrylochinolin do wytwarzania srodków antybakteryjnych

Legal Events

Date Code Title Description
FA Abandonment or withdrawal